GHAZALEH ESKANDARI to Neoplasms
This is a "connection" page, showing publications GHAZALEH ESKANDARI has written about Neoplasms.
Connection Strength
0.060
-
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246.
Score: 0.060
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.